Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

By J. Keane, Sharon K. Gershon, R. Wise, E. Mirabile-Levens, J. Kasznica, W. Schwieterman, J. Siegel, M. Braun. 2001

2,330 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Binding and functional comparisons of two types of tumor necrosis factor antagonists. (2002, background): “…important distinctions in the safety profiles of these two products, most notably an increased risk of specific types of infection for infliximab (Keane et al., 2001) or etanercept (Fisher et al., 1996; Song et al., 2001), or possibly an increased risk of neurological disorders for etanercept…”
TNF Regulates Chemokine Induction Essential for Cell Recruitment, Granuloma Formation, and Clearance of Mycobacterial Infection1 (2002, background): “tuberculosis infection in humans is graphically illustrated by the rapid reactivation of clinical tuberculosis in patients undergoing treatment for rheumatoid arthritis and Crohn’s disease with a humanized mAb to TNF (37).”
Development of anti-TNF therapy for rheumatoid arthritis (2002, background): “But, interfering with the immune system comes at a price, and there is concern that infections with intracellular organisms such as Mycobacterium tuberculosis are increased in anti-TNF-treated patient”
Points of control in inflammation (2002, background): “Corticosteroids taught this lesson, and TNF-neutralizing agents reinforced i”
The spectrum of latent tuberculosis: rethinking the goals of prophylaxis (2009, neutral): “Finally, TNF neutralization, which is used to treat certain inflammatory diseases in humans, substantially increases the risk of TB reactivatio”